|display ongoing studies|
|Study||Ref.||Design||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results|
COVID-19 mild to moderate meta-analysis
|RCT||lenzilumab||placebo||COVID-19 mild to moderate||some concern||261/259||conclusif|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).